{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:36:34Z","timestamp":1773765394460,"version":"3.50.1"},"reference-count":174,"publisher":"Impact Journals, LLC","issue":"35","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,8,30]]},"DOI":"10.18632\/oncotarget.10033","type":"journal-article","created":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T13:28:34Z","timestamp":1465997314000},"page":"57327-57350","source":"Crossref","is-referenced-by-count":23,"title":["Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies"],"prefix":"10.18632","volume":"7","author":[{"given":"Elisabetta","family":"Fratta","sequence":"first","affiliation":[{"name":"Cancer Bio-Immunotherapy Unit, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, PN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Montico","sequence":"additional","affiliation":[{"name":"Cancer Bio-Immunotherapy Unit, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, PN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Cancer Bio-Immunotherapy Unit, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, PN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Colizzi","sequence":"additional","affiliation":[{"name":"Cancer Bio-Immunotherapy Unit, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, PN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Sigalotti","sequence":"additional","affiliation":[{"name":"Cancer Bio-Immunotherapy Unit, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, PN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Dolcetti","sequence":"additional","affiliation":[{"name":"Cancer Bio-Immunotherapy Unit, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, PN, Italy"},{"name":"University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,6,14]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Ebert","year":"2011","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Chiba","year":"2014","journal-title":"Leukemia"},{"key":"3","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Reed","year":"2009","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia","volume":"366","author":"Cherry","year":"2012","journal-title":"The New England journal of medicine"},{"key":"5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.febslet.2009.04.012","article-title":"CpG islands--\u2018a rough guide\u2019","volume":"583","author":"Bird","year":"2009","journal-title":"FEBS Lett"},{"key":"6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrg3354","article-title":"DNA methylation: roles in mammalian development","volume":"14","author":"Meissner","year":"2013","journal-title":"Nat Rev Genet"},{"key":"7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-380866-0.60002-2","article-title":"DNA methylation and cancer","volume":"70","author":"Esteller","year":"2010","journal-title":"Adv Genet"},{"key":"8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cca.2011.02.013","article-title":"Advances in DNA methylation: 5-hydroxymethylcytosine revisited","volume":"412","author":"Guldberg","year":"2011","journal-title":"Clin Chim Acta"},{"key":"9","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1182\/blood-2013-04-427724","article-title":"Perspectives and future directions for epigenetics in hematology","volume":"121","author":"Godley","year":"2013","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/ng.463","article-title":"DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction","volume":"41","author":"Rosenbauer","year":"2009","journal-title":"Nat Genet"},{"key":"11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng.1009","article-title":"Dnmt3a is essential for hematopoietic stem cell differentiation","volume":"44","author":"Godley","year":"2012","journal-title":"Nat Genet"},{"key":"12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/leu.2012.168","article-title":"Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report","volume":"27","author":"Meshinchi","year":"2013","journal-title":"Leukemia"},{"key":"13","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1182\/blood-2011-07-367961","article-title":"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia","volume":"119","author":"Delwel","year":"2012","journal-title":"Blood"},{"key":"14","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A Mutations in Acute Myeloid Leukemia","volume":"363","author":"Koboldt","year":"2010","journal-title":"The New England journal of medicine"},{"key":"15","unstructured":"Thirukonda V, Raghupathy, Parekh. Translational Medicine. 2012."},{"key":"16","first-page":"1324","article-title":"DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias","volume":"87","author":"Lubbert","year":"2002","journal-title":"Haematologica"},{"key":"17","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bcmd.2007.09.005","article-title":"p15Ink4b: dual function in myelopoiesis and inactivation in myeloid disease","volume":"40","author":"Wolff","year":"2008","journal-title":"Blood Cells Mol Dis"},{"key":"18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.seminhematol.2013.01.001","article-title":"Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes","volume":"50","author":"Verma","year":"2013","journal-title":"Semin Hematol"},{"key":"19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.leukres.2008.08.014","article-title":"Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms","volume":"33","author":"Hofmann","year":"2009","journal-title":"Leuk Res"},{"key":"20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/gcc.10092","article-title":"Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma","volume":"35","author":"Visakorpi","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"key":"21","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1038\/sj.onc.1205651","article-title":"DNA methylation in cancer: too much but also too little","volume":"21","author":"Ehrlich","year":"2002","journal-title":"Oncogene"},{"key":"22","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1038\/sj.onc.1208866","article-title":"Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense\/antisense transcription and marks the progression of chronic myeloid leukemia","volume":"24","author":"Torres","year":"2005","journal-title":"Oncogene"},{"key":"23","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Lacombe","year":"2009","journal-title":"N Engl J Med"},{"key":"24","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood-2010-03-274704","article-title":"Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins but indicates no definite prognostic value","volume":"116","author":"Mufti","year":"2010","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2012-10-451237","article-title":"The role of chromatin modifiers in normal and malignant hematopoiesis","volume":"121","author":"Dent","year":"2013","journal-title":"Blood"},{"key":"26","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3324\/haematol.2013.092007","article-title":"Epigenetics in the hematologic malignancies","volume":"99","author":"Dawson","year":"2014","journal-title":"Haematologica"},{"key":"27","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bbagrm.2014.03.001","article-title":"Interpreting the language of histone and DNA modifications","volume":"1839","author":"Strahl","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"28","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0955-0674(02)00387-3","article-title":"Histone mRNA expression: multiple levels of cell cycle regulation and important developmental consequences","volume":"14","author":"Duronio","year":"2002","journal-title":"Curr Opin Cell Biol"},{"key":"29","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nrm2861","article-title":"Histone variants--ancient wrap artists of the epigenome","volume":"11","author":"Henikoff","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"30","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrg2438","article-title":"Metabolism and regulation of canonical histone mRNAs: life without a poly(A) tail","volume":"9","author":"Duronio","year":"2008","journal-title":"Nat Rev Genet"},{"key":"31","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.molcel.2014.02.014","article-title":"Nucleosomes are context-specific H2A Z-modulated barriers to RNA polymerase","volume":"53","author":"Henikoff","year":"2014","journal-title":"Mol Cell"},{"key":"32","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1101\/gr.106542.110","article-title":"Changes in H2A Z occupancy and DNA methylation during B-cell lymphomagenesis","volume":"20","author":"Henikoff","year":"2010","journal-title":"Genome Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/ejh.12039","article-title":"Somatic mutation of H3F3A a chromatin remodeling gene is rare in acute leukemias and non-Hodgkin lymphoma","volume":"90","author":"Lee","year":"2013","journal-title":"European Journal of Haematology"},{"key":"34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00018-013-1343-z","article-title":"Histone variants: emerging players in cancer biology","volume":"71","author":"Bernstein","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"35","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/1055-9965.EPI-06-0639","article-title":"Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphoma","volume":"16","author":"Brooks-Wilson","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1101\/gad.255182.114","article-title":"Chromatin signatures of cancer","volume":"29","author":"Shilatifard","year":"2015","journal-title":"Genes Dev"},{"key":"37","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2013-02-483727","article-title":"Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing","volume":"122","author":"Taylor","year":"2013","journal-title":"Blood"},{"key":"38","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1182\/blood-2013-05-500264","article-title":"Mutations in linker histone genes HIST1H1 B C D and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma","volume":"123","author":"Cimmino","year":"2014","journal-title":"Blood"},{"key":"39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrg3173","article-title":"Histone methylation: a dynamic mark in health disease and inheritance","volume":"13","author":"Shi","year":"2012","journal-title":"Nat Rev Genet"},{"key":"40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0092-8674(02)00976-5","article-title":"Histone methyltransferase activity of a Drosophila Polycomb group repressor complex","volume":"111","author":"Simon","year":"2002","journal-title":"Cell"},{"key":"41","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Ott","year":"2013","journal-title":"Cancer Cell"},{"key":"42","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1182\/blood-2010-04-280149","article-title":"EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis","volume":"116","author":"Elemento","year":"2010","journal-title":"Blood"},{"key":"43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin","volume":"42","author":"Kimbara","year":"2010","journal-title":"Nature genetics"},{"key":"44","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity to increase H3K27 trimethylation","volume":"117","author":"Morin","year":"2011","journal-title":"Blood"},{"key":"45","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas","volume":"107","author":"Copeland","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/2040620712466864","article-title":"Epigenetic therapy of hematological malignancies: where are we now?","volume":"4","author":"Licht","year":"2013","journal-title":"Therapeutic Advances in Hematology"},{"key":"47","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms","volume":"25","author":"Tefferi","year":"2011","journal-title":"Leukemia"},{"key":"48","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes","volume":"42","author":"Jansen","year":"2010","journal-title":"Nat Genet"},{"key":"49","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Boultwood","year":"2010","journal-title":"Nat Genet"},{"key":"50","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1182\/blood.V98.4.1264","article-title":"A novel gene NSD1 is fused to NUP98 in the t(5;11)(q35;p15 5) in de novo childhood acute myeloid leukemia","volume":"98","author":"Wainscoat","year":"2001","journal-title":"Blood"},{"key":"51","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/ncb1608","article-title":"NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis","volume":"9","author":"Kamps","year":"2007","journal-title":"Nat Cell Biol"},{"key":"52","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1080\/10428190600822128","article-title":"Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma","volume":"47","author":"Pilarski","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"53","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1158\/0008-5472.CAN-13-1000","article-title":"NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma","volume":"73","author":"Dai","year":"2013","journal-title":"Cancer Res"},{"key":"54","doi-asserted-by":"crossref","first-page":"8603","DOI":"10.1073\/pnas.0503072102","article-title":"Global and Hox-specific roles for the MLL1 methyltransferase","volume":"102","author":"Young","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"55","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2008.002436","article-title":"The molecular biology of mixed lineage leukemia","volume":"94","author":"Slany","year":"2009","journal-title":"Haematologica"},{"key":"56","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/leu.2009.33","article-title":"New insights to the MLL recombinome of acute leukemias","volume":"23","author":"Balgobind","year":"2009","journal-title":"Leukemia"},{"key":"57","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-007-0009-8","article-title":"Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia","volume":"87","author":"Hess","year":"2008","journal-title":"Int J Hematol"},{"key":"58","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations histone modifications and leukaemia stem-cell development","volume":"7","author":"Armstrong","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"59","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood-2012-11-465120","article-title":"Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l","volume":"121","author":"Armstrong","year":"2013","journal-title":"Blood"},{"key":"60","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/ncb1642","article-title":"Protein arginine-methyltransferase-dependent oncogenesis","volume":"9","author":"So","year":"2007","journal-title":"Nat Cell Biol"},{"key":"61","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Gould","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Rabadan","year":"2011","journal-title":"Nature"},{"key":"63","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Alizadeh","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"64","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic heterogeneity of diffuse large B-cell lymphoma","volume":"110","author":"Flowers","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"65","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1756-8722-2-28","article-title":"RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression","volume":"2","author":"Geyer","year":"2009","journal-title":"J Hematol Oncol"},{"key":"66","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1101\/gad.870101","article-title":"Tumor formation and inactivation of RIZ1 an Rb-binding member of a nuclear protein-methyltransferase superfamily","volume":"15","author":"Huang","year":"2001","journal-title":"Genes Dev"},{"key":"67","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1073\/pnas.93.4.1642","article-title":"Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family","volume":"93","author":"Nucifora","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"68","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1074\/jbc.272.5.2984","article-title":"The retinoblastoma interacting zinc finger gene RIZ produces a PR domain-lacking product through an internal promoter","volume":"272","author":"Huang","year":"1997","journal-title":"J Biol Chem"},{"key":"69","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/bjc.1996.583","article-title":"Expression of the zinc finger gene EVI-1 in ovarian and other cancers","volume":"74","author":"Taetle","year":"1996","journal-title":"Br J Cancer"},{"key":"70","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrn3427","article-title":"Histone acetylation: molecular mnemonics on the chromatin","volume":"14","author":"Tsai","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"71","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1182\/blood-2008-04-152017","article-title":"The histone acetyl transferase activity of monocytic leukemia zinc finger is critical for the proliferation of hematopoietic precursors","volume":"113","author":"Lacaud","year":"2009","journal-title":"Blood"},{"key":"72","doi-asserted-by":"crossref","first-page":"17124","DOI":"10.1074\/jbc.M602633200","article-title":"MOZ-TIF2 alters cofactor recruitment and histone modification at the RARbeta2 promoter: differential effects of MOZ fusion proteins on CBP- and MOZ-dependent activators","volume":"281","author":"Heery","year":"2006","journal-title":"J Biol Chem"},{"key":"73","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1535-6108(03)00051-5","article-title":"MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP","volume":"3","author":"Gilliland","year":"2003","journal-title":"Cancer Cell"},{"key":"74","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/MCB.25.3.988-1002.2005","article-title":"MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function","volume":"25","author":"Heery","year":"2005","journal-title":"Mol Cell Biol"},{"key":"75","doi-asserted-by":"crossref","first-page":"14789","DOI":"10.1073\/pnas.232568499","article-title":"Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal","volume":"99","author":"Livingston","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"76","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.molcel.2007.02.019","article-title":"Phosphorylation of CBP by IKK Promotes Cell Growth by Switching the Binding Preference of CBP from p53 to NF-B","volume":"26","author":"Chen","year":"2007","journal-title":"Molecular Cell"},{"key":"77","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.exphem.2007.07.015","article-title":"MOZ and MOZ-CBP cooperate with NF-B to activate transcription from NF-B-dependent promoters","volume":"35","author":"Gabig","year":"2007","journal-title":"Experimental Hematology"},{"key":"78","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1177\/1947601911417176","article-title":"Histone modifiers in cancer: friends or foes?","volume":"2","author":"Schneider","year":"2011","journal-title":"Genes Cancer"},{"key":"79","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4155\/fmc.12.80","article-title":"Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives","volume":"4","author":"Rodriquez","year":"2012","journal-title":"Future Med Chem"},{"key":"80","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1177\/1947601913483767","article-title":"The diversity of histone versus nonhistone sirtuin substrates","volume":"4","author":"Vaquero","year":"2013","journal-title":"Genes Cancer"},{"key":"81","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Johnstone","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"82","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histone deacetylases (HDACs) in human cancer","volume":"1","author":"Esteller","year":"2007","journal-title":"Mol Oncol"},{"key":"83","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1038\/sj.onc.1204336","article-title":"Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?","volume":"20","author":"Pelicci","year":"2001","journal-title":"Oncogene"},{"key":"84","doi-asserted-by":"crossref","first-page":"7186","DOI":"10.1038\/sj.onc.1204766","article-title":"Translocations of the RARalpha gene in acute promyelocytic leukemia","volume":"20","author":"Licht","year":"2001","journal-title":"Oncogene"},{"key":"85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7","article-title":"Histone deacetylases transcriptional control and cancer","volume":"184","author":"Seto","year":"2000","journal-title":"J Cell Physiol"},{"key":"86","doi-asserted-by":"crossref","first-page":"8792","DOI":"10.1158\/0008-5472.CAN-08-4481","article-title":"PML-RAR{alpha} and Dnmt3a1 cooperate in vivo to promote acute promyelocytic leukemia","volume":"70","author":"Blelloch","year":"2010","journal-title":"Cancer Res"},{"key":"87","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Pelicci","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"88","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/bfgp\/elr002","article-title":"Dynamics of epigenetic modifications in leukemia","volume":"10","author":"Di","year":"2011","journal-title":"Brief Funct Genomics"},{"key":"89","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrc2943","article-title":"Acute promyelocytic leukaemia: novel insights into the mechanisms of cure","volume":"10","author":"Chen","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"90","first-page":"104631","article-title":"Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications","volume":"2011","author":"Bruserud","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"91","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1128\/MCB.01365-08","article-title":"Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA","volume":"29","author":"Chen","year":"2009","journal-title":"Mol Cell Biol"},{"key":"92","doi-asserted-by":"crossref","first-page":"E159","DOI":"10.1073\/pnas.1102140108","article-title":"Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes","volume":"108","author":"Blobel","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"93","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.febslet.2012.04.045","article-title":"The bromodomain interaction module","volume":"586","author":"Knapp","year":"2012","journal-title":"FEBS Lett"},{"key":"94","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","article-title":"Histone recognition and large-scale structural analysis of the human bromodomain family","volume":"149","author":"Knapp","year":"2012","journal-title":"Cell"},{"key":"95","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Roberts","year":"2011","journal-title":"Nature"},{"key":"96","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cell.2013.07.013","article-title":"BET bromodomains mediate transcriptional pause release in heart failure","volume":"154","author":"Haldar","year":"2013","journal-title":"Cell"},{"key":"97","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Young","year":"2013","journal-title":"Cell"},{"key":"98","doi-asserted-by":"crossref","first-page":"43137","DOI":"10.1074\/jbc.M112.413047","article-title":"Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells","volume":"287","author":"Chin","year":"2012","journal-title":"J Biol Chem"},{"key":"99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OTT.S7222","article-title":"An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes","volume":"3","author":"Godley","year":"2010","journal-title":"Onco Targets Ther"},{"key":"100","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/1947601910365081","article-title":"DNA demethylating antineoplastic strategies: a comparative point of view","volume":"1","author":"Fanelli","year":"2010","journal-title":"Genes Cancer"},{"key":"101","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/leu.2013.173","article-title":"Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia","volume":"27","author":"Estey","year":"2013","journal-title":"Leukemia"},{"key":"102","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/j.seminhematol.2012.08.001","article-title":"Clinical results with the DNA hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update","volume":"49","author":"Lubbert","year":"2012","journal-title":"Semin Hematol"},{"key":"103","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","article-title":"Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in hematopoietic malignancies","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"104","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421 8921 and 9221 by the Cancer and Leukemia Group B","volume":"24","author":"Larson","year":"2006","journal-title":"J Clin Oncol"},{"key":"105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised open-label phase III study","volume":"10","author":"Zimmerman","year":"2009","journal-title":"Lancet Oncol"},{"issue":"Suppl 3","key":"106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-011-0002-8","article-title":"Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia","volume":"28","author":"Font","year":"2011","journal-title":"Adv Ther"},{"key":"107","article-title":"An update of current treatments for adult acute myeloid leukemia","author":"Gardin","year":"2015","journal-title":"Blood"},{"key":"108","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/CMAR.S40600","article-title":"Decitabine in the treatment of acute myeloid leukemia in elderly patients","volume":"6","author":"Cashen","year":"2014","journal-title":"Cancer Manag Res"},{"key":"109","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/CCO.0000000000000231","article-title":"Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia","volume":"27","author":"Fianchi","year":"2015","journal-title":"Curr Opin Oncol"},{"key":"110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-1-4419-9967-2_13","article-title":"Epigenetic therapies in MDS and AML","volume":"754","author":"Gore","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"111","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/cncr.21796","article-title":"Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2\u2032-deoxycytidine retreatment in high-risk myelodysplasia patients","volume":"106","author":"Lubbert","year":"2006","journal-title":"Cancer"},{"key":"112","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Saba","year":"2007","journal-title":"Blood"},{"key":"113","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia","volume":"28","author":"DiPersio","year":"2010","journal-title":"J Clin Oncol"},{"key":"114","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1158\/1535-7163.MCT-09-1048","article-title":"S110 a 5-Aza-2\u2032-deoxycytidine-containing dinucleotide is an effective DNA methylation inhibitor in vivo and can reduce tumor growth","volume":"9","author":"Jones","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"115","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00262-012-1365-7","article-title":"Immunomodulatory activity of SGI-110 a 5-aza-2\u2032-deoxycytidine-containing demethylating dinucleotide","volume":"62","author":"Maio","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"116","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1177\/1087057111421212","article-title":"Epigenetic drug discovery: targeting DNA methyltransferases","volume":"17","author":"Kanner","year":"2012","journal-title":"J Biomol Screen"},{"key":"117","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1479-5876-8-92","article-title":"S110 a novel decitabine dinucleotide increases fetal hemoglobin levels in baboons (P anubis)","volume":"8","author":"DeSimone","year":"2010","journal-title":"J Transl Med"},{"key":"118","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/leu.2014.244","article-title":"Novel drugs for older patients with acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2015","journal-title":"Leukemia"},{"key":"119","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.2010.08213.x","article-title":"Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation","volume":"150","author":"Byrd","year":"2010","journal-title":"Br J Haematol"},{"key":"120","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-10-1893","article-title":"Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas","volume":"17","author":"Siu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"121","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-08-2196","article-title":"Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas","volume":"15","author":"Wistuba","year":"2009","journal-title":"Clin Cancer Res"},{"key":"122","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.1234769","article-title":"Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation","volume":"340","author":"Quivoron","year":"2013","journal-title":"Science"},{"key":"123","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1078-0432.CCR-15-0362","article-title":"Molecular Pathways: IDH2 Mutations-Co-opting Cellular Metabolism for Malignant Transformation","volume":"22","author":"Stein","year":"2016","journal-title":"Clin Cancer Res"},{"key":"124","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1868-7083-5-12","article-title":"Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents","volume":"5","author":"Bruserud","year":"2013","journal-title":"Clin Epigenetics"},{"key":"125","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2003-12-4333","article-title":"Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid","volume":"104","author":"Gattermann","year":"2004","journal-title":"Blood"},{"key":"126","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","article-title":"Phase 1\/2 study of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid in patients with leukemia","volume":"108","author":"Estey","year":"2006","journal-title":"Blood"},{"key":"127","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","article-title":"Safety and clinical activity of the combination of 5-azacytidine valproic acid and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome","volume":"110","author":"Garcia-Manero","year":"2007","journal-title":"Blood"},{"key":"128","doi-asserted-by":"publisher","first-page":"34","DOI":"10.18632\/oncotarget.106","article-title":"Phase 2 clinical trial of 5-azacitidine valproic acid and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome","volume":"1","author":"Fenaux","year":"2010","journal-title":"Oncotarget"},{"key":"129","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/leu.2012.312","article-title":"Azacitidine fails to eradicate leukemic stem\/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia","volume":"27","author":"Brookes","year":"2013","journal-title":"Leukemia"},{"key":"130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Frankel","year":"2007","journal-title":"Blood"},{"key":"131","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"29","author":"Newman","year":"2011","journal-title":"J Clin Oncol"},{"key":"132","doi-asserted-by":"crossref","first-page":"e53766","DOI":"10.1371\/journal.pone.0053766","article-title":"Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms","volume":"8","author":"Almeida","year":"2013","journal-title":"PLoS One"},{"key":"133","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.0022-202X.2005.23925.x","article-title":"Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"125","author":"Duvic","year":"2005","journal-title":"J Invest Dermatol"},{"key":"134","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.exphem.2007.06.009","article-title":"Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis","volume":"35","author":"Chen","year":"2007","journal-title":"Exp Hematol"},{"key":"135","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3324\/haematol.2014.117473","article-title":"A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"100","author":"Kirschbaum","year":"2015","journal-title":"Haematologica"},{"key":"136","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ctrv.2015.04.003","article-title":"The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies","volume":"43","author":"Dimopoulos","year":"2016","journal-title":"Cancer Treatment Reviews"},{"key":"137","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","article-title":"Panobinostat for the Treatment of Multiple Myeloma","volume":"21","author":"Richardson","year":"2015","journal-title":"Clin Cancer Res"},{"key":"138","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1182\/blood-2007-10-117762","article-title":"The novel histone deacetylase inhibitor LBH589 induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells","volume":"111","author":"Jove","year":"2008","journal-title":"Blood"},{"key":"139","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.leukres.2011.10.020","article-title":"LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism","volume":"36","author":"Grant","year":"2012","journal-title":"Leuk Res"},{"key":"140","doi-asserted-by":"crossref","first-page":"e79106","DOI":"10.1371\/journal.pone.0079106","article-title":"Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1 CHK1 and Rad51","volume":"8","author":"Ge","year":"2013","journal-title":"PLoS One"},{"key":"141","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1038\/bcj.2013.68","article-title":"Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"4","author":"Spencer","year":"2014","journal-title":"Blood Cancer J"},{"key":"142","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"Allen","year":"2015","journal-title":"J Clin Oncol"},{"key":"143","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.2147\/OTT.S59269","article-title":"Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma","volume":"7","author":"Reddy","year":"2014","journal-title":"Onco Targets Ther"},{"key":"144","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/2040620715592567","article-title":"Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review","volume":"6","author":"O'Connor","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"145","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.3109\/10428194.2013.877134","article-title":"A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study","volume":"55","author":"Newman","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"146","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00277-011-1240-1","article-title":"Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)","volume":"91","author":"DiPersio","year":"2012","journal-title":"Ann Hematol"},{"key":"147","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1182\/blood-2011-02-336891","article-title":"HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL","volume":"118","author":"O'Connor","year":"2011","journal-title":"Blood"},{"key":"148","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.leukres.2014.06.007","article-title":"Orphan drug designation for pracinostat volasertib and alvocidib in AML","volume":"38","author":"Grant","year":"2014","journal-title":"Leuk Res"},{"key":"149","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrd1930","article-title":"Epigenetic therapy of cancer: past present and future","volume":"5","author":"Jones","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"150","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1200\/JCO.2013.50.3102","article-title":"Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905","volume":"32","author":"Gore","year":"2014","journal-title":"J Clin Oncol"},{"key":"151","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.exphem.2011.07.002","article-title":"The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors","volume":"39","author":"Younes","year":"2011","journal-title":"Exp Hematol"},{"key":"152","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/bjh.13318","article-title":"Entinostat a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents","volume":"169","author":"Hernandez-Ilizaliturri","year":"2015","journal-title":"Br J Haematol"},{"key":"153","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Jaffe","year":"2009","journal-title":"J Clin Oncol"},{"key":"154","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal open-label phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Balser","year":"2012","journal-title":"J Clin Oncol"},{"key":"155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Balser","year":"2014","journal-title":"J Hematol Oncol"},{"key":"156","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1158\/1078-0432.CCR-07-0318","article-title":"Tolerability pharmacodynamics and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes","volume":"14","author":"Nimer","year":"2008","journal-title":"Clin Cancer Res"},{"key":"157","first-page":"959","article-title":"A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia","volume":"105","author":"Wright","year":"2005","journal-title":"Blood"},{"key":"158","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1038\/bcj.2015.83","article-title":"Romidepsin targets multiple survival signaling pathways in malignant T cells","volume":"5","author":"Andersson","year":"2015","journal-title":"Blood Cancer J"},{"key":"159","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4149\/neo_2011_02_118","article-title":"Synergistic apoptotic effect of arabinoxylan rice bran (MGN-3\/Biobran) and curcumin (turmeric) on human multiple myeloma cell line U266 in vitro","volume":"58","author":"Gollapudi","year":"2011","journal-title":"Neoplasma"},{"key":"160","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.molonc.2012.09.004","article-title":"Trials with \u2018epigenetic\u2019 drugs: an update","volume":"6","author":"Altucci","year":"2012","journal-title":"Mol Oncol"},{"key":"161","first-page":"185","article-title":"Curcumin differs from tetrahydrocurcumin for molecular targets signaling pathways and cellular responses","volume":"20","author":"Prasad","year":"2015","journal-title":"Molecules"},{"key":"162","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1158\/1535-7163.MCT-07-0159","article-title":"Characterization of novel inhibitors of histone acetyltransferases","volume":"6","author":"Jung","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"163","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/oxfordjournals.jbchem.a002901","article-title":"Tip60 is a cell-type-specific transcriptional regulator","volume":"129","author":"Brabletz","year":"2001","journal-title":"J Biochem"},{"key":"164","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood-2009-03-213496","article-title":"Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells","volume":"114","author":"Bhalla","year":"2009","journal-title":"Blood"},{"key":"165","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McHugh","year":"2012","journal-title":"Nature"},{"key":"166","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nchembio.1084","article-title":"A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells","volume":"8","author":"Moyer","year":"2012","journal-title":"Nat Chem Biol"},{"key":"167","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Tseng","year":"2011","journal-title":"Cancer Cell"},{"key":"168","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Pollock","year":"2013","journal-title":"Blood"},{"key":"169","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nature09589","article-title":"Suppression of inflammation by a synthetic histone mimic","volume":"468","author":"Lee","year":"2010","journal-title":"Nature"},{"key":"170","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"West","year":"2010","journal-title":"Nature"},{"key":"171","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Bergsagel","year":"2011","journal-title":"Cell"},{"key":"172","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Sims","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"173","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Brown","year":"2011","journal-title":"Nature"},{"key":"174","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2012-02-413021","article-title":"BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia","volume":"120","author":"Weinstock","year":"2012","journal-title":"Blood"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T16:55:49Z","timestamp":1718643349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,14]]},"references-count":174,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2016,8,30]]}},"alternative-id":["10033","27329599"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.10033","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,14]]}}}